Sertindole

Overview

Sertindole, sold under the brand name Serdolect among others, is an antipsychotic medication. Sertindole was developed by the Danish pharmaceutical company Lundbeck and marketed under license by Abbott Labs. Like other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. WP

Sertindole is not approved for use in the United States and was discontinued in Australia in January 2014. WP⚠ Wikipedia itself has flagged this text: citation needed.

Drug class

Atypical antipsychotic WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

Sertindole appears effective as an antipsychotic in schizophrenia. In a 2013 study in a comparison of 15 antipsychotic drugs in effectivity in treating schizophrenic symptoms, sertindole was found to be slightly less effective than haloperidol, quetiapine, and aripiprazole, as effective as ziprasidone, approximately as effective as chlorpromazine and asenapine, and slightly more effective than lurasidone and iloperidone.[1][2] WP

Risks and side effects

Adverse effects

Very common (>10% incidence) adverse effects include:[3] WP

• Headache[3] WP
• Ejaculation failure[3] WP
• Insomnia[3] WP
• Dizziness[3] WP

Common (1–10% incidence) adverse effects include:[3] WP

• Urine that tests positive for red and/or white blood cells[3] WP
• Sedation (causes less sedation than most antipsychotic drugs according to a recent meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs. Causes only slightly [and non-significantly] more sedation than amisulpride and paliperidone)[2][4] WP
• Ejaculation disorder[3] WP
• Erectile dysfunction[3] WP
• Orthostatic hypotension[4] WP
• Weight gain (which it seems to possess a similar propensity for causing as quetiapine)[2] WP

Uncommon (0.1–1% incidence) adverse effects include:[3] WP

• Substernal chest pain[3] WP
• Face oedema[3] WP
• Influenza-like illness[3] WP
• Neck rigidity[3] WP
• Pallor[3] WP
• Peripheral vascular disorder[3] WP
• syncope[3] WP
• Torsades de pointes[3] WP
• Vasodilation[3] WP
• Suicide attempt[3] WP
• Amnesia[3] WP
• Anxiety[3] WP
• Ataxia[3] WP
• Confusion[3] WP
• Incoordination[3] WP
• Libido decreased[3] WP
• Libido increased[3] WP
• Miosis[3] WP
• Nystagmus[3] WP
• Personality disorder[3] WP
• Psychosis[3] WP
• Reflexes decreased[3] WP
• Reflexes increased[3] WP
• Stupor[3] WP
• Suicidal tendency[3] WP
• Urinary retention[3] WP
• Vertigo[3] WP
• Diabetes mellitus[3] WP
• Abnormal stools[3] WP
• Gastritis[3] WP
• Gingivitis[3] WP
• Glossitis[3] WP
• Increased appetite[3] WP
• Mouth ulceration[3] WP
• Rectal disorder[3] WP
• Rectal haemorrhage[3] WP
• Stomatitis[3] WP
• Tongue disorder[3] WP
• Ulcerative stomatitis[3] WP
• Anaemia[3] WP
• Ecchymosis[3] WP
• Hypochromic anaemia[3] WP
• Leukopenia[3] WP
• Hyperglycaemia[3] WP
• Hyperlipemia[3] WP
• Oedema[3] WP
• Bone pain[3] WP
• Myasthenia[3] WP
• Twitching[3] WP
• Bronchitis[3] WP
• Hyperventilation[3] WP
• Pneumonia[3] WP
• Sinusitis[3] WP
• Furunculosis[3] WP
• Herpes simplex[3] WP
• Nail disorder[3] WP
• Psoriasis[3] WP
• Pustular Rash[3] WP
• Skin discolouration[3] WP
• Skin hypertrophy[3] WP
• Skin ulcer[3] WP
• Abnormal vision[3] WP
• Keratoconjunctivitis[3] WP
• Lacrimation disorder[3] WP
• Otitis externa[3] WP
• Pupillary disorder[3] WP
• Taste perversion[3] WP
• Anorgasmia[3] WP
• Penis disorder (gs)[3] WP
• Urinary urgency[3] WP
• Hyperprolactinaemia (which it seems to cause with a higher propensity than most other atypical antipsychotics do)[2] WP
• Seizures[3] WP
• Galactorrhoea[3] WP

Rare (<0.1% incidence) adverse effects include:[3] WP

• Neuroleptic malignant syndrome[3] WP
• Tardive dyskinesia[3] WP

Unknown frequency adverse events include:[3] WP

• Extrapyramidal side effects (EPSE; e.g. dystonia, akathisia, muscle rigidity, parkinsonism, etc. These adverse effects are probably uncommon/rare according to a recent meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs which found it had the 2nd lowest effect size for causing EPSE)[2] WP
• Venous thromboembolism[3] WP
• QT interval prolongation (probably common; in a recent meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs it was found to be the most prone to causing QT interval prolongation)[2] WP

Pharmacology

Pharmacology

Sertindole is metabolized in the body to dehydrosertindole. Sertindole has also been reported to interact with tubulin and inhibit its polymerization.[5][6] WP

Chemistry

Formula

C24H26ClFN4O PC

CAS number

106516-24-9 PC

Molar mass (g/mol)

440.9 PC

IUPAC name (computed by PubChem)

1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one PC

SMILES

C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O PC

InChIKey

GZKLJWGUPQBVJQ-UHFFFAOYSA-N PC

PubChem CID

60149

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. The Cochrane Database of Systematic Reviews. July 2005. doi:10.1002/14651858.CD001715.pub2 · PMID 16034864 · PMC7025766
2. Journal / agency Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. September 2013. doi:10.1016/S0140-6736(13)60733-3 · PMID 23810019
3. Other PRODUCT INFORMATION SERDOLECT TABLETS. 16 January 2013
4. Other Taylor D, Paton C, Shitij K. The Maudsley prescribing guidelines in psychiatry. 2012
5. Other TRC | Details of CAS = 173294-84-3, ChemicalName = Dehydrosertindole, synonym = 1-[2-[4-[5-Chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]-1,3-dihydro-2H-Imidazol-2-one; Lu 28-092, MolFormula = C24H24ClFn4O
6. Journal / agency Baksheeva VE, La Rocca R, Allegro D, Derviaux C, Pasquier E, Roche P, Morelli X, Devred F, Golovin AV, Tsvetkov PO. NanoDSF Screening for Anti-tubulin Agents Uncovers New Structure–Activity Insights. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01008

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.